The establishment of polypeptide PSMA‐targeted chimeric antigen receptor‐engineered natural killer cells for castration‐resistant prostate cancer and the induction of ferroptosis‐related cell death

The mortality of castration‐resistant prostate cancer (CRPC) is high due to lack of an effective treatment. Chimeric antigen receptor (CAR)‐based therapy is a promising immunotherapeutic strategy. Here, we aimed to design a novel CAR‐natural killer (NK) cells with a clinically significant tumoricidal effect on CRPC.

[1]  Yang Xu,et al.  CD70‐targeting CAR‐T cells have potential activity against CD19‐negative B‐cell Lymphoma , 2021, Cancer communications.

[2]  Ruihua Xu,et al.  Cancer incidence, mortality, and burden in China: a time‐trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020 , 2021, Cancer communications.

[3]  Yue Yang,et al.  SEMA3A-mediated crosstalk between prostate cancer cells and tumor-associated macrophages promotes androgen deprivation therapy resistance , 2021, Cellular & molecular immunology.

[4]  A. Rosato,et al.  Anti-PSMA CAR-Engineered NK-92 Cells: An Off-the-Shelf Cell Therapy for Prostate Cancer , 2020, Cells.

[5]  D. Campana,et al.  NK cells for cancer immunotherapy , 2020, Nature Reviews Drug Discovery.

[6]  A. Chinnaiyan,et al.  CD8+ T cells regulate tumor ferroptosis during cancer immunotherapy , 2019, Nature.

[7]  Qiong Zhang,et al.  GSCALite: a web server for gene set cancer analysis , 2018, Bioinform..

[8]  D. Kaufman,et al.  Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. , 2018, Cell stem cell.

[9]  G. Peng,et al.  Reciprocal Network between Cancer Stem-Like Cells and Macrophages Facilitates the Progression and Androgen Deprivation Therapy Resistance of Prostate Cancer , 2018, Clinical Cancer Research.

[10]  L. Gan,et al.  Extracellular matrix protein 1 promotes cell metastasis and glucose metabolism by inducing integrin β4/FAK/SOX2/HIF-1α signaling pathway in gastric cancer , 2018, Oncogene.

[11]  Ximing J. Yang,et al.  Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8+ T-cells Derived from Patients with Metastatic Castrate-resistant Disease. , 2017, European urology.

[12]  D. Bollino,et al.  Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy. , 2017, Translational research : the journal of laboratory and clinical medicine.

[13]  R. Weichselbaum,et al.  Tumour ischaemia by interferon-γ resembles physiological blood vessel regression , 2017, Nature.

[14]  E. Seifried,et al.  Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies , 2017, Cancer Immunology, Immunotherapy.

[15]  B. Qin,et al.  Discovery of PSMA-specific peptide ligands for targeted drug delivery. , 2016, International journal of pharmaceutics.

[16]  M. Geyer,et al.  CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. , 2016, Blood.

[17]  Christine E Brown,et al.  Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. , 2016, Blood.

[18]  D. Maloney,et al.  Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. , 2016, Blood.

[19]  S. Grupp,et al.  CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia , 2016, Current Treatment Options in Oncology.

[20]  E. Crawford,et al.  Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies. , 2015, The Journal of urology.

[21]  M. Caligiuri,et al.  CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells , 2015, Scientific Reports.

[22]  Lewis L. Lanier,et al.  NK cells and cancer: you can teach innate cells new tricks , 2015, Nature Reviews Cancer.

[23]  Biao Xu,et al.  Longitudinal trends in prostate cancer incidence, mortality, and survival of patients from two Shanghai city districts: a retrospective population-based cohort study, 2000–2009 , 2014, BMC Public Health.

[24]  M. Caligiuri,et al.  CS1-Specific Chimeric Antigen Receptor (CAR)-Engineered Natural Killer Cells Enhance In Vitro and In Vivo Anti-tumor Activity Against Human Multiple Myeloma , 2013, Leukemia.

[25]  D. Torigian,et al.  Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies , 2013, Cancer Immunology Research.

[26]  S. Rosenberg,et al.  Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors , 2013, Nature Reviews Clinical Oncology.

[27]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[28]  W. Wilson,et al.  B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.

[29]  M. Cheng,et al.  Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor , 2011, Cancer Gene Therapy.

[30]  H. Mühl,et al.  IL-2 Stimulated but Not Unstimulated NK Cells Induce Selective Disappearance of Peripheral Blood Cells: Concomitant Results to a Phase I/II Study , 2011, PloS one.

[31]  Michel Sadelain,et al.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.

[32]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[33]  H. Ljunggren,et al.  NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy , 2008, Cancer Immunology, Immunotherapy.

[34]  H. Ljunggren,et al.  Prospects for the use of NK cells in immunotherapy of human cancer , 2007, Nature Reviews Immunology.

[35]  J. Isaacs,et al.  A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. , 2006, Cancer research.

[36]  J. Quian,et al.  Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. , 2004, Histology and histopathology.

[37]  M. Caligiuri,et al.  Immunotherapeutic approaches for hematologic malignancies. , 2004, Hematology. American Society of Hematology. Education Program.

[38]  I. Pastan,et al.  Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  A. Scott,et al.  Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. , 1997, Molecular immunology.